Proposed Directors of Tirupati Graphite explain why they have requisitioned an GM. Watch the video here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The financial report is on the website under investors section and shareholders documents 👍
Cheers Steg, I'm out and about today I can't seem to access it on my mobile. Fingers crossed Eric has got some big news ro go along with confirmation of the suspension being lifted. Gl holders...Excitement building!!! ;-)
@monstermunch. I had trouble finding it because it isn’t in the drop down menu at the top right of the home screen. If you scroll all the way to the bottom of the home page and click the investors link you’ll find it there.
Cheers MumbleG, certainly hidden away, but very encouraging nonetheless, nothing we didn't know although underlines exciting prospects and potential going forward. Gl :-)
Money, if you get access to the document, it shows last month 2 of the non dilutive grant tranches were received totalling approx €1.1m. I’m assuming that it’s so buried in the annual report, that the market won’t yet catch on, so if they reinstate us, with the recent dilution, it’s a great opportunity for us to fill our boots as cash runway is covered for the next 12 months.
Nice one Porter, and great if Eric has more good news to deliver. Gl :-)
Genflow Biosciences Plc, a biotechnology company focusing on longevity research and age-related diseases, has released its final results for the year ending 31 December 2023. The company has received significant non-dilutive research grants from the Government of Wallonia in Belgium, completed a successful fundraise, and made strategic progress with its key research programs in MASH and Werner Syndrome. These achievements, alongside the expansion of their intellectual property portfolio and collaborations with other biotech firms, highlight Genflow’s commitment to advancing its research pipeline and financial stability.
I guess we'll find out tomorrow if any big news is up Eric's sleeve. The accounts were only 4 working days late, and so intriguing Eric decided to suspend shares on the 1st May, rather than simply annouce they would be one week late because of audit delays, unforeseen circumstances beyond their control, unrelated to cash flow and/or economic position.
The first payment of €777,000 from the 2.89m Euros grant is due to be received imminently, and so an RNS confirming this will be very well received, but still hoping for something even bigger and the reason for the ongoing suspension, despite the release of the accounts, whereby it stops those in the know and their mates from buying in before the event. Just a thought, but any major player/investor would certainly prefer it that way I reckon. Anyways, regardless of what may come, Genflow’s prospects and potential are looking very nice and I for one will be holding and adding for great things to come. Gla :-)
Very intriguing we're still in suspension and so I wonder who the other interested parties are??? :>]
"unedited text of its final results for the year ended 31 December 2023, announced earlier today( yesterday), to assist shareholders and other interested parties."
8 May 2024
Genflow Biosciences Plc
Restoration of Listing
Genflow Biosciences Plc (LSE:GENF) (OTCQB:GENFF) ("Genflow" or "the Company"), an emerging leader in the field of longevity research, focused on developing therapeutic solutions for the prevention of age-related diseases, is pleased to announce that, following publication of the audited financial statements for the year ended 31 December 2023 (FY23 Results) on 7 May 2024, and having completed the upload of the FY23 Results to the Financial Conduct Authority's National Storage Mechanism at www.fca.org.uk/markets/primary-markets/regulatory-disclosures/national-storage-mechanism, it has been advised by the FCA that the temporary suspension of listing of the Company's ordinary shares on the Official List of the Financial Conduct Authority is expected to be lifted later today, 8 May 2024, and that the listing on the Main Market of the London Stock Exchange, of the ordinary shares, will be restored.
So, the suspension was just down to bureaucratic delays of the audit.
Yes, that was always clear and it was requested by the company rather than enforced by the FCA.
Yep, but big news could still drop at anytime. Gla holders:-)
Genflow Biosciences (LON:GENF) (OTCQB:GENFF)
1,600 followers
13h
This past week, the XBI rose 7.8%, marking its strongest gain in 10 weeks. Tim Opler of Stifel Financial Corp. compares it to the start of the Q1 rally, suggesting this could be a rally year for biotech.
With Genflow Biosciences (LON:GENF) (OTCQB:GENFF)'s numerous recent grants and exciting treatment development, the company is poised to capitalize on the movement.
Read more here: hTtps://loom.ly/EbVSZBU